ENANTA PHARMACEUTICALS INC's ticker is ENTA and the CUSIP is 29251M106. A total of 170 filers reported holding ENANTA PHARMACEUTICALS INC in Q1 2022. The put-call ratio across all filers is 0.43 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $6,306,202 | -4.1% | 564,566 | +83.7% | 0.00% | 0.0% |
| Q2 2023 | $6,576,262 | +23.2% | 307,302 | +132.9% | 0.00% | 0.0% |
| Q1 2023 | $5,335,978 | -17.2% | 131,948 | -4.7% | 0.00% | 0.0% |
| Q4 2022 | $6,444,183 | -31.6% | 138,525 | -23.8% | 0.00% | 0.0% |
| Q3 2022 | $9,422,000 | -18.6% | 181,674 | -25.8% | 0.00% | -50.0% |
| Q2 2022 | $11,576,000 | -2.3% | 244,874 | +47.0% | 0.00% | 0.0% |
| Q1 2022 | $11,854,000 | +25.7% | 166,548 | +32.1% | 0.00% | +100.0% |
| Q4 2021 | $9,427,000 | +2.3% | 126,069 | -22.3% | 0.00% | 0.0% |
| Q3 2021 | $9,217,000 | +18.8% | 162,232 | -7.9% | 0.00% | 0.0% |
| Q2 2021 | $7,756,000 | +7.8% | 176,207 | +20.8% | 0.00% | 0.0% |
| Q1 2021 | $7,194,000 | +8.1% | 145,851 | -7.8% | 0.00% | 0.0% |
| Q4 2020 | $6,658,000 | +61.1% | 158,156 | +75.2% | 0.00% | 0.0% |
| Q3 2020 | $4,132,000 | +32.1% | 90,255 | +44.9% | 0.00% | 0.0% |
| Q2 2020 | $3,127,000 | -10.8% | 62,272 | -8.6% | 0.00% | 0.0% |
| Q1 2020 | $3,506,000 | -76.0% | 68,168 | -71.1% | 0.00% | -66.7% |
| Q4 2019 | $14,590,000 | +46.0% | 236,158 | +42.0% | 0.00% | 0.0% |
| Q3 2019 | $9,993,000 | +8.7% | 166,310 | +52.6% | 0.00% | +50.0% |
| Q2 2019 | $9,194,000 | +24.0% | 108,964 | +40.4% | 0.00% | 0.0% |
| Q1 2019 | $7,416,000 | -45.5% | 77,629 | -59.6% | 0.00% | -50.0% |
| Q4 2018 | $13,608,000 | +299.1% | 192,136 | +381.7% | 0.00% | +300.0% |
| Q3 2018 | $3,410,000 | -43.2% | 39,890 | -22.9% | 0.00% | -50.0% |
| Q2 2018 | $6,000,000 | +28.8% | 51,767 | -10.1% | 0.00% | +100.0% |
| Q1 2018 | $4,659,000 | +69.7% | 57,575 | +23.1% | 0.00% | 0.0% |
| Q4 2017 | $2,745,000 | +72.5% | 46,769 | +37.6% | 0.00% | – |
| Q3 2017 | $1,591,000 | +43.3% | 33,995 | +10.2% | 0.00% | – |
| Q2 2017 | $1,110,000 | -53.1% | 30,840 | -59.9% | 0.00% | – |
| Q1 2017 | $2,368,000 | -29.6% | 76,852 | -23.5% | 0.00% | -100.0% |
| Q4 2016 | $3,366,000 | +2304.3% | 100,520 | +1813.9% | 0.00% | – |
| Q3 2016 | $140,000 | -28.6% | 5,252 | -41.2% | 0.00% | – |
| Q2 2016 | $196,000 | -3.0% | 8,926 | +29.7% | 0.00% | – |
| Q1 2016 | $202,000 | -43.3% | 6,882 | -36.0% | 0.00% | – |
| Q4 2015 | $356,000 | +140.5% | 10,754 | +162.4% | 0.00% | – |
| Q3 2015 | $148,000 | -34.5% | 4,099 | -18.3% | 0.00% | – |
| Q2 2015 | $226,000 | -15.0% | 5,016 | -42.3% | 0.00% | – |
| Q1 2015 | $266,000 | -54.5% | 8,695 | -24.2% | 0.00% | – |
| Q4 2014 | $584,000 | +226.3% | 11,475 | +154.0% | 0.00% | – |
| Q3 2014 | $179,000 | -13.9% | 4,518 | -6.4% | 0.00% | – |
| Q2 2014 | $208,000 | 0.0% | 4,829 | -7.5% | 0.00% | – |
| Q1 2014 | $208,000 | +22.4% | 5,219 | -16.2% | 0.00% | – |
| Q4 2013 | $170,000 | -78.0% | 6,225 | -85.7% | 0.00% | – |
| Q2 2013 | $773,000 | – | 43,678 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Krensavage Asset Management, LLC | 476,042 | $45,472,000 | 12.29% |
| Stonepine Capital Management, LLC | 60,840 | $5,811,000 | 3.34% |
| ACUTA CAPITAL PARTNERS, LLC | 61,000 | $5,827,000 | 2.77% |
| Virtus ETF Advisers LLC | 10,634 | $1,016,000 | 2.16% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 61,000 | $5,827,000 | 2.15% |
| ARMISTICE CAPITAL, LLC | 372,000 | $35,533,000 | 1.94% |
| Matarin Capital Management, LLC | 209,403 | $20,002,000 | 1.46% |
| Monashee Investment Management LLC | 50,000 | $4,776,000 | 1.10% |
| Granahan Investment Management | 151,322 | $14,454,000 | 0.78% |
| ALGERT GLOBAL LLC | 13,186 | $1,260,000 | 0.72% |